{"schema_version":"secwatch.filing_event.v1","accession":"0000917520-23-000012","form_type":"8-K","ticker":"IART","cik":"0000917520","company_name":"INTEGRA LIFESCIENCES HOLDINGS CORP","filed_at":"2023-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.567286+00:00","generated_at":"2026-06-19T06:07:13.073697+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Integra LifeSciences Q4 adj EPS $0.94, rev $398M; FY2023 guidance rev $1.60-1.62B, adj EPS $3.43-3.51","bullets":["Q4 2022 revenues $398.0M (-1.8% reported, +2.9% organic); GAAP EPS $0.63, adj EPS $0.94.","Full-year 2022 revenues $1,557.7M (+1.0% reported, +4.2% organic); GAAP EPS $2.16, adj EPS $3.36.","FY2023 guidance: revenues $1,602M-$1,620M (organic growth 4.0%-5.2%), adj EPS $3.43-$3.51.","Entered $150M accelerated share repurchase agreement with Goldman Sachs, expected to complete in H1 2023.","Codman Specialty Surgical organic growth 1.8%; Tissue Technologies organic growth 5.0% in Q4."],"urls":{"canonical":"https://secwatch.observer/filing/0000917520-23-000012","json":"https://secwatch.observer/filing/0000917520-23-000012.json","markdown":"https://secwatch.observer/filing/0000917520-23-000012.md","text":"https://secwatch.observer/filing/0000917520-23-000012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/917520/000091752023000012/0000917520-23-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/917520/000091752023000012/iart-20230222.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T06:07:13.073697+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"31ecff82d9c540b109fce1a23288b4cfd232cd5e","claim":"INTEGRA LIFESCIENCES HOLDINGS CORP reported Q4 2022 results: revenue $398.0 million, net income $52.9 million, EPS $0.63.","evidence_excerpt":"Total reported revenues for the fourth quarter were $398.0 million, a decrease of 1.8% from the fourth quarter of 2021. Fourth quarter organic revenues increased 2.9% over the prior year. The Company reported GAAP net income of $52.9 million, or $0.63 per diluted share, in the fourth quarter of 2022, compared to GAAP net income of $45.4 million, or $0.53 per diluted share, in the prior year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/917520/000091752023000012/0000917520-23-000012-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Q4 2022"},{"label":"Revenue","value":"$398.0 million"},{"label":"Net income","value":"$52.9 million"},{"label":"EPS","value":"$0.63"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"9a43ddd1b1e4b58ee693ab2eb9ed7e7e73be205c","claim":"INTEGRA LIFESCIENCES HOLDINGS CORP reported FY2023 results: revenue $1,602 million to $1,620 million. Guidance initiated.","evidence_excerpt":"For the full-year 2023, the Company expects revenues to be in a range of $1,602 million to $1,620 million, representing reported growth of approximately 2.9% to 4.0% and organic growth in the range of 4.0% to 5.2%.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/917520/000091752023000012/0000917520-23-000012-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"FY2023"},{"label":"Revenue","value":"$1,602 million to $1,620 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"d4cdd47240ebd353e4f68bcac77fea32406437ff","claim":"INTEGRA LIFESCIENCES HOLDINGS CORP reported FY2022 results: revenue $1,557.7 million, net income $180.6 million, EPS $2.16.","evidence_excerpt":"to $0.53 in the fourth quarter 2021. • Adjusted earnings per diluted share were $0.94, compared to $0.84 in the fourth quarter of 2021. Full-Year 2022 • Reported revenues were 1,557.7 million representing an increase of 1.0% on a reported basis and an increase of 4.2% on an organic basis compared to full-year 2021. • GAAP earnings per diluted share wer e $2.16,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/917520/000091752023000012/0000917520-23-000012-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"FY2022"},{"label":"Revenue","value":"$1,557.7 million"},{"label":"Net income","value":"$180.6 million"},{"label":"EPS","value":"$2.16"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}